SHR-1209 + Placebo

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia

Trial Timeline

Jun 20, 2019 → Dec 22, 2020

NCT ID

NCT03944109

About SHR-1209 + Placebo

SHR-1209 + Placebo is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03944109. Target conditions include Hyperlipidemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03944109	Phase 1/2	Completed	Jun 20, 2019	Dec 22, 2020	Hyperlipidemia
NCT03634436	Phase 1	Completed	Aug 30, 2018	May 28, 2019	Hypercholesteremia

Competing Products

20 competing products in Hyperlipidemia

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebo	Viking Therapeutics	Phase 2	47
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	77
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo	Yuhan	Phase 3	77
Diet+pravastatin	Daiichi Sankyo	Approved	85
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	85
Minute Maid Heart Wise orange juice + Welchol	Daiichi Sankyo	Approved	85
Pravafen + Pravastatin + Fenofibrate	Shionogi	Phase 3	77
Evacetrapib + Atorvastatin + Ezetimibe + Placebo	Eli Lilly	Phase 3	77
exenatide	Eli Lilly	Pre-clinical	23
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SC	Eli Lilly	Phase 1	33
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209	Jiangsu Hengrui Medicine	Phase 1	33
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 2	52
Rosuvastatin (Crestor)	AstraZeneca	Approved	85
simvastatin + Ezetimibe	Merck	Approved	85
MK-0524A + Atorvastatin + Simvastatin	Merck	Phase 3	77
simvastatin 20 mg/ezetimibe	Merck	Phase 2/3	65
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin	Merck	Phase 3	77
Sitagliptin + Placebo	Merck	Phase 2/3	65
100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) + Placebo + 300 mg inclisiran sodium (equivalent to 284 mg inclisiran)	Novartis	Phase 1	33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved